Health Condition 1: null- type 2 diabetes
Conditions
Interventions
Intervention1: Pioglitazone: 45 mg/day of pioglitazone orally after food in three divided doses for 12 weeks
Sponsors
RSSDI
Eligibility
Inclusion criteria
Inclusion criteria: Patients attending diabetic clinic or endocrine out patient department (OPD) services of SSKM Hospital and IPGMER will be considered. Patients of type 2 diabetes not controlled (fasting sugar >110, Post prandial > 180 or HbA1C >6.5) on medical nutrition therapy and metformin would be undertaken for the study
Exclusion criteria
Exclusion criteria: 1)Patients with very poorly controlled sugars i.e. HbA1C more than 8 will not be enrolled since glycosuria is associated with hypercaiciuria and control of glycemic status with pioglitazone can decrease calcium excretion and confound results 2)Patients taking insulin and/or other anti-diabetic drugs will be excluded. Patients on ACE inhibitors and diuretics will be excluded as will patients having blood pressures above 180systolic or diastolic above 110 mm Hg 3)Also patients with associated disorders like primary hyperparathyroidism, chronic kidney disease, liver disease, any chronic illness, malignancy, chronic drug use like anti-epileptic agents, oral contraceptive pills, steroids which are likely to interfere with vitamin-D metabolism will be excluded. 4)Patients with pregnancy would be excluded. Patients on calcium or vitamin-D supplementation would also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) effect on urinary calcium and phosphate excretion 2) effect on serum vitamin D and 1,25 vitamin D levelsTimepoint: 1) effect on urinary calcium and phosphate excretion 2) effect on serum vitamin D and 1,25 vitamin D levels | — |
Secondary
| Measure | Time frame |
|---|---|
| effect on glycemic controlTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactAnubhav Thukral
Professor, Dept of Endocrinology & Metabolism (THESIS GUIDE)
Outcome results
None listed